Can cabozantinib be used after pazopanib resistance?

Whether cabozantinib can be used after pazopanib resistance is a question that many patients and doctors are concerned about.

Pazopanib is an oral multi-target tyrosine kinase inhibitor that exerts anti-tumor effects by inhibiting tumor cell proliferation and angiogenesis. However, long-term use of pazopanib may lead to the occurrence of drug resistance, which is mainly due to multiple reasons such as genetic mutations of tumor cells, activation of other survival signaling pathways, and changes in the tumor microenvironment.

Cabozantinib, also as a multi-target tyrosine kinase inhibitor, has the ability to inhibit a variety of tyrosine kinases related to tumor growth and metastasis, including but not limited to RET, MET, VEGFR, etc. It has demonstrated good therapeutic effects in a variety of solid tumors, especially in thyroid cancer, kidney cancer and liver cancer.

When pazopanib resistance develops, cabozantinib could theoretically be considered as an alternative treatment. Because cabozantinib has a different mechanism of action and target, it may still be effective against tumor cells that are resistant to pazopanib. Additionally, cabozantinib has shown significant therapeutic efficacy in clinical trials, particularly in certain tumor types.

However, the decision to use cabozantinib needs to be evaluated on a patient-specific basis. Physicians need to consider factors such as the patient's physical condition, disease progression, response to previous treatments, and possible adverse effects. At the same time, cabozantinib may also cause some adverse reactions, such as diarrhea, stomatitis, etc., which require close attention and timely treatment.